83 completed, 27 terminated, 12 active not recruiting, 11 unknown. 97 Phase 2, 64 Phase 1, 13 Phase 3, 5 Phase 4, 2 Early Phase 1.
Follow ixazomib: new trials by email Literature Review of ixazomib trials Research Report on ixazomib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir Size Ixazomib 4 mg, Placebo - HIV (Human Immunodeficiency Virus) | Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 45 | 2026-11-23 | 2026-10-19 |
| SIL as Maintenance Therapy in Multiple Myeloma Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy - Multiple Myeloma | Phase 2 | Not yet recruiting | Navy General Hospital, Beijing | 50 | 2025-01-01 | 2024-12-20 |
| Trial of Ixazomib for Kaposi Sarcoma Ixazomib Citrate, Quality-of-Life Assessment, Questionnaire Administration - Kaposi Sarcoma, Skin | Phase 2 | Recruiting | AIDS Malignancy Consortium | 41 | 2023-11-07 | 2026-02-27 |
| Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma Mezigdomide, Ixazomib, Dexamethasone - Relapsed and Refractory Multiple Myeloma | Phase 1 / Phase 2 | Withdrawn | Kathleen Dorritie | 2023-10-02 | 2024-11-19 | |
| Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD) - Multiple Myeloma | Phase 3 | Terminated | Universitätsklinikum Hamburg-Eppendorf | 28 | 2023-03-03 | 2026-01-05 |
| Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg - AL Amyloidosis | Phase 1 / Phase 2 | Active not recruiting | Columbia University | 53 | 2022-10-26 | 2026-10-08 |
| Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography - Recurrent AL Amyloidosis, Refractory AL Amyloidosis | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-08-03 | 2026-07-31 |
| Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma Ixazomib plus low-dose lenalidomide, Ixazomib - Multiple Myeloma | Phase 4 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2022-07-01 | 2026-01-05 |
| A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma Ixazomib, Pomalidomide, Lenalidomide - Multiple Myeloma | Phase 4 | Withdrawn | Takeda | 2022-06-30 | 2022-05-03 | |
| Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Multiple Myeloma | Phase 3 | Completed | National Cancer Institute (NCI) | 1 | 2022-02-16 | 2025-05-23 |
| A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." Ixazomib, Iberdomide, Dexamethasone Oral - Multiple Myeloma at First Relapse | Phase 2 | Active not recruiting | Nantes University Hospital | 75 | 2021-12-14 | 2026-06-15 |
| A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients Ixazomib - Systemic Sclerosis, Scleroderma | Phase 2 | Terminated | Michael M. Pham | 4 | 2021-04-28 | 2025-04-06 |
| Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Selinexor, Ixazomib - Liposarcoma, Malignant Peripheral Nerve Sheath Tumors | Phase 1 | Withdrawn | Matthew Ingham | 2020-11-01 | 2020-11-27 | |
| Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) Ixazomib - Precursor Cell Lymphoblastic Leukemia-lymphoma | Phase 1 | Withdrawn | Millennium Pharmaceuticals, Inc. | 2020-10-31 | 2020-09-28 | |
| Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM Lenalidomide, Ixazomib, Daratumumab Injection - Myeloma, Multiple | Phase 2 | Active not recruiting | Alliance Foundation Trials, LLC. | 79 | 2020-10-21 | 2025-12-18 |
| Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance - Multiple Myeloma | Phase 3 | Unknown | University of Leeds | 740 | 2020-08-04 | 2021-06-15 |
| Tasquinimod for the Treatment of Relapsed or Refractory Myeloma Tasquinimod, IRd chemotherapy - Multiple Myeloma | Phase 1 | Terminated | University of Pennsylvania | 30 | 2020-07-10 | 2025-10-07 |
| SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis Ixazomib (NINLARO®) capsules / Matching placebo capsules - Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 1 | Recruiting | Queen Mary University of London | 72 | 2020-06-15 | 2026-09-08 |
| Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia Zanubrutinib,Ixazomib and Dexamethasone - Waldenström Macroglobulinemia | Phase 2 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 25 | 2020-06-01 | 2026-02-11 |
| Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma Nivolumab, Ixazomib, Dexamethasone - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Terminated | Andrew Yee, MD | 2 | 2020-02-14 | 2023-08-21 |
Showing 20 of 152. Sign in to see all of them.
Multiple Myeloma (85) · Recurrence (11) · Lymphoma (8) · Immunoglobulin Light-chain Amyloidosis (6) · Leukemia, Myeloid, Acute (6) · Lymphoma, Mantle-Cell (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Waldenstrom Macroglobulinemia (4) · Amyloidosis (3) · Hematologic Neoplasms (3) · Neoplasms, Plasma Cell (3) · Acquired Immunodeficiency Syndrome (2) · Breast Neoplasms (2) · Carcinoma, Renal Cell (2) · Leukemia, Biphenotypic, Acute (2)
Millennium Pharmaceuticals, Inc. (20) · Takeda (14) · Mayo Clinic (11) · M.D. Anderson Cancer Center (9) · National Cancer Institute (NCI) (5) · Emory University (4) · Memorial Sloan Kettering Cancer Center (4) · University of Leeds (3) · Alliance for Clinical Trials in Oncology (2) · Arbeitsgemeinschaft medikamentoese Tumortherapie (2) · Dana-Farber Cancer Institute (2) · Dartmouth-Hitchcock Medical Center (2) · Ehab L Atallah (2) · Fred Hutchinson Cancer Center (2) · Massachusetts General Hospital (2)
United States (113) · France (17) · Canada (15) · United Kingdom (13) · Spain (12) · Germany (10) · Greece (8) · Italy (8) · Japan (8) · Sweden (8) · Belgium (7) · Czechia (7) · South Korea (7) · Australia (6) · China (6)
Shaji Kumar, M.D. (4) · Andrew Yee, MD (2) · Ajai Chari, MD (1) · Ajay K. Gopal (1) · Ajay Nooka, MD, MPH (1) · Amrita Krishnan (1) · Andrzej Jakubowiak (1) · Angela Dispenzieri, M.D. (1) · Anjali Advani (1) · Anuj Mahindra, MD (1)
PMID 28803351, PMID 28550039, PMID 36130300, PMID 40226119, PMID 24904120, PMID 24920586, PMID 25456369, PMID 26337806, PMID 26872892, PMID 27002117, PMID 27119237, PMID 27702799, PMID 28683766, PMID 28751562, PMID 28783865, PMID 28800141, PMID 28932928, PMID 29054911, PMID 29661775, PMID 29954932, PMID 30352784, PMID 30400780, PMID 30460684, PMID 30471652, PMID 30545780, PMID 31558804, PMID 31880006, PMID 32145111, PMID 32613281, PMID 32653622, PMID 32777064, PMID 32822482, PMID 32874573, PMID 33021870, PMID 33641211, PMID 33763699, PMID 34111952, PMID 34559902, PMID 34587246, PMID 34599726, PMID 35075109, PMID 35172566, PMID 35654466, PMID 35737873, PMID 35840087, PMID 36180329, PMID 36385536, PMID 36650020, PMID 36708469, PMID 36762851
2016 (4), 2018 (4), 2014 (3), P30CA138292 (3), 2017 (1), P30CA014599 (1), P30CA015083 (1), P30CA015704 (1), P30CA043703 (1), P30CA060553 (1), P30CA124435 (1), U01HL069294 (1), U10CA031946 (1), U10CA180820 (1), U10CA180821 (1)